PMID- 21102326
OWN - NLM
STAT- MEDLINE
DCOM- 20110418
LR  - 20211020
IS  - 1473-6535 (Electronic)
IS  - 0957-9672 (Print)
IS  - 0957-9672 (Linking)
VI  - 22
IP  - 1
DP  - 2011 Feb
TI  - Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid 
      perspective.
PG  - 55-61
LID - 10.1097/MOL.0b013e328341a5a8 [doi]
AB  - PURPOSE OF REVIEW: To examine the results of the Action to Control Cardiovascular 
      Risk in Diabetes (ACCORD)-Lipid trial, particularly the subgroup analyses. It is 
      important, when a study fails to meet its overall primary endpoint, to ensure 
      that interpretation of the results include analyses of subgroups that might 
      benefit from the treatment tested. The goal of this review, therefore, is to 
      provide insight and advice to physicians and healthcare workers treating patients 
      similar to those enrolled in ACCORD. RECENT FINDINGS: The recently published 
      results of ACCORD-Lipid trial will be presented upon the background of previous 
      trials that have tested the ability of fibrates to lower cardiovascular risk. 
      SUMMARY: Although ACCORD-Lipid trial did not provide support for the general 
      addition of fenofibrate to statin-treated patients with type 2 diabetes mellitus 
      (T2DM), it added significantly to the results from fibrate monotherapy trials 
      indicative of benefit from such treatment in subgroups of patients who present 
      with significant dyslipidemia. In particular, ACCORD-Lipid trial, in our view, 
      supports the addition of fenofibrate to statin therapy in patients with T2DM and 
      optimal low-density lipoprotein cholesterol levels but persistent, significant 
      hypertriglyceridemia (>200 mg/dl) and low high-density lipoprotein cholesterol 
      levels (<35-40 mg/dl).
FAU - Elam, Marshall
AU  - Elam M
AD  - Department of Pharmacology, University of Tennessee Health Sciences 
      Center-Memphis, Memphis, Tennessee, USA.
FAU - Lovato, Laura C
AU  - Lovato LC
FAU - Ginsberg, Henry
AU  - Ginsberg H
LA  - eng
GR  - N01HC95184/HL/NHLBI NIH HHS/United States
GR  - Y01 HC001010/HC/NHLBI NIH HHS/United States
GR  - N01-HC-95180/HC/NHLBI NIH HHS/United States
GR  - Y01 HC009035/HC/NHLBI NIH HHS/United States
GR  - IAAY1-HC-9035/HC/NHLBI NIH HHS/United States
GR  - R01 DK075504/DK/NIDDK NIH HHS/United States
GR  - IAAY1-HC-1010/HC/NHLBI NIH HHS/United States
GR  - N01HC95181/HL/NHLBI NIH HHS/United States
GR  - N01-HC-95182/HC/NHLBI NIH HHS/United States
GR  - N01-HC-95178/HC/NHLBI NIH HHS/United States
GR  - N01HC95182/HL/NHLBI NIH HHS/United States
GR  - N01-HC-95181/HC/NHLBI NIH HHS/United States
GR  - N01HC95178/HL/NHLBI NIH HHS/United States
GR  - N01HC95183/HL/NHLBI NIH HHS/United States
GR  - N01-HC-95184/HC/NHLBI NIH HHS/United States
GR  - R01 HL073030/HL/NHLBI NIH HHS/United States
GR  - N01HC95179/HL/NHLBI NIH HHS/United States
GR  - N01-HC-95183/HC/NHLBI NIH HHS/United States
GR  - N01HC95180/HL/NHLBI NIH HHS/United States
GR  - N01-HC-95179/HC/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - England
TA  - Curr Opin Lipidol
JT  - Current opinion in lipidology
JID - 9010000
RN  - 0 (Hypolipidemic Agents)
RN  - U202363UOS (Fenofibrate)
SB  - IM
MH  - Cardiovascular Diseases/*prevention & control
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Fenofibrate/therapeutic use
MH  - Humans
MH  - Hypolipidemic Agents/therapeutic use
PMC - PMC6067007
MID - NIHMS742944
EDAT- 2010/11/26 06:00
MHDA- 2011/04/19 06:00
PMCR- 2018/07/31
CRDT- 2010/11/25 06:00
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2011/04/19 06:00 [medline]
PHST- 2018/07/31 00:00 [pmc-release]
AID - 10.1097/MOL.0b013e328341a5a8 [doi]
PST - ppublish
SO  - Curr Opin Lipidol. 2011 Feb;22(1):55-61. doi: 10.1097/MOL.0b013e328341a5a8.